AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02437604
Drug: Treatment C Flovent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOVENT DISKUS 250 mcg, 2 inhalations
Trial: NCT02437604
Drug: Treatment D: Advair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVAIR DISKUS 500/50 mcg, 1 inhalation
Trial: NCT01295736
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills TID per os during 90 days
Trial: NCT00064766
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03187834
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children in this arm will receive Azithromycin once a day.
Trial: NCT03187834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children in this arm will receive Placebo once a day.
Trial: NCT00841048
Drug: AZD4017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ascending multiple doses(start dose 75mg od), oral suspension
Trial: NCT00841048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02921386
Drug: Oral Testosterone Undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
Trial: NCT03333317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive oral administration of matching placebo.
Trial: NCT03279523
Drug: F 18 T807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Trial: NCT02075047
Drug: placebo oral capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
Trial: NCT03498820
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous short-acting opioid routinely administered during general anesthesia
Trial: NCT02821377
Drug: Hypertonic saline solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
Trial: NCT03405935
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food.
Trial: NCT03397134
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as a single dose once daily
Trial: NCT02757443
Drug: Phosphocreatine sodium tetrahydrate after anaesthesia induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
Trial: NCT02757443
Drug: 5% Glucose after anaesthesia induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
Trial: NCT02757443
Drug: Phosphocreatine sodium tetrahydrate added to cardioplegia
RxNorm normalized name: Phosphocreatine
DrugBank: Phosphocreatine (DB13191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
Trial: NCT02757443
Drug: Phosphocreatine sodium tetrahydrate after heart recovery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
Trial: NCT02757443
Drug: 5% Glucose after heart recovery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
Trial: NCT02757443
Drug: Phosphocreatine sodium tetrahydrate after ICU admission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
Trial: NCT02757443
Drug: 5% Glucose after ICU admission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
Trial: NCT03287674
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Trial: NCT03383783
Drug: 0 ppm F (placebo, negative control)
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Trial: NCT03383783
Drug: 250 ppm F as NaF (dose-response control)
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Trial: NCT03383783
Drug: 500 ppm F as NaF (dose-response control)
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Trial: NCT03383783
Drug: 1100 ppm F as NaF (positive control)
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the four treatment periods in the crossover study design.
Trial: NCT01703117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-22 subjects between the ages of 60-85 will receive placebo
Trial: NCT01342965
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and gemcitabine were locally sourced with commercial products.
Trial: NCT02978703
Drug: COPD Pharmacologic Substance
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
Trial: NCT01646619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
Trial: NCT02046070
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide tablets
Trial: NCT00315107
Drug: Alesse
RxNorm normalized name: Alesse
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02516826
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02516826
Drug: Combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin/Olmesartan(Combination)
Trial: NCT02516826
Drug: Placebo of Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02516826
Drug: Placebo of Rosuvastatin/Olmesartan(Combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03521713
Drug: EPORON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS
Trial: NCT03521713
Drug: EPREX
RxNorm normalized name: Eprex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS
Trial: NCT01873053
Drug: WIN-34B
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
Trial: NCT01873053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00343863
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00343863
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04130399
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
Trial: NCT00052312
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03634371
Drug: Drug Levothyroxine 150 mcg
RxNorm normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of a 600 mcg levothyroxine dose
Trial: NCT03634371
Drug: Drug Eutirox 150 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a 600 mcg levothyroxine dose
Trial: NCT00404170
Drug: B-CIT and SPECT imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional ongoing B-CIT SPECT imaging scans at follow-up visits
Trial: NCT01549795
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine - administered till liver transplantation
Trial: NCT03283397
Drug: EK-12
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
Trial: NCT00086502
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
Trial: NCT02183129
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02183129
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01945775
Drug: Physician's-Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine, Eribulin, Gemcitabine or Vinorelbine
Trial: NCT00650520
Drug: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Trial: NCT04139681
Drug: A. Vogels Sore Throat lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 times 1 A. Vogels sore throat lozenges daily for 4 days
Trial: NCT00110487
Drug: ERB-041
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02251132
Drug: TPV low 1
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02251132
Drug: TPV low 2
RxNorm normalized name: Dianeal Low Calcium 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02251132
Drug: TPV medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02251132
Drug: Radiolabelled erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04008511
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m2 bid po for 14 days.
Trial: NCT00803972
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant human hyaluronidase PH20
Trial: NCT01817790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle for Fluticasone propionate aqueous nasal spray
Trial: NCT02418988
Drug: TACE plus rAd-p53 artery injection
RxNorm normalized name: SUS SCROFA ARTERY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
Trial: NCT02097342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet placebo per oral, once daily will be given to 10 patients for 6 months
Trial: NCT00003847
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00652899
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.
Trial: NCT03254277
Drug: 3BNC117-LS
RxNorm normalized name: Emcor LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3BNC117-LS
Trial: NCT03254277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04214886
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is is an anti-cancer drug acting as an alkylating agent that is used to treat leukemia and lymphoma cancers.
Trial: NCT00844805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00844805
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00494559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug with the same appearance as actos
Trial: NCT00034879
Drug: ZD1839 (Gefitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00857948
Drug: Placebo, vehicle control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application followed by thorough rinsing of the hair and scalp with water.
Trial: NCT00605553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules~Placebo for 7 days
Trial: NCT01889134
Drug: Sedron (alendronate)
RxNorm normalized name: Simaba cedron whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00023751
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00023751
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01400243
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch
Trial: NCT03726853
Drug: CKD-497 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of CKD-497
Trial: NCT03726853
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT03726853
Drug: Comparator placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator placebo
Trial: NCT01175200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator similar to lansoprazole
Trial: NCT04346030
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultrasound guided steroid injection using 1ml of 10mg triamcinolone acetonide (Shincort) mixed with 1ml of 2% lidocaine hydrochloride (Xylocaine) and 8cc NS
Trial: NCT02193087
Drug: TDV Liquid Formulation 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDV Liquid Formulation 2 for subcutaneous injection
Trial: NCT02193087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDV liquid formulation placebo-matching solution for subcutaneous injection
Trial: NCT02737995
Drug: Ferric carboxymaltose infusion
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
Trial: NCT02715726
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT02715726
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT01707992
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
Trial: NCT00600769
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage dependent on clinical factors such as age, weight and patient-specific health status
Trial: NCT02226549
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Trial: NCT02654002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT03349866
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 bid d1-14
Trial: NCT04196946
Drug: 25 mcg fentanyl
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group I received 10 mg hyperbaric bupivacaine (2 cc) and 25 mcg fentanyl (0.5 cc).
Trial: NCT02008357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00627536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched to avotermin dosage strength
Trial: NCT00755534
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
Trial: NCT03242018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
Trial: NCT00088790
Drug: AZD5438
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03362697
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
Trial: NCT00806923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv on day 1 of each 3 week cycle until disease progression
Trial: NCT00131456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03527628
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
Trial: NCT03823846
Drug: Routine Dynastat or Flurbiprofen Axetil jinjection
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
Trial: NCT03823846
Drug: Adjusted Dynastat or Flurbiprofen Axetil jinjection
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
Trial: NCT03823846
Drug: normal analgesia pump administration
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of analgesia pump was added if needed.
Trial: NCT03823846
Drug: adjusted analgesia pump administration
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
Trial: NCT03899064
Drug: Induction: Application of MC2-01 Cream, irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation